FY2025 · ended Dec 31, 2025 · Revenue $2.00M, +49.3% YoY · Filed Mar 26, 2026
Oramed Pharmaceuticals Inc. (ORMP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.0 million and net income of $64.0 million. Free cash flow was -$9.2 million. As of Jun 30, 2026 it held $38.0 million in cash and investments and $733,000 in total debt.
Revenue
$2.00M
+49.3% vs prior year
Net income
$64.05M
+436.0% vs prior year
Operating cash flow (TTM)
$-5.21M
+67.6% vs year-ago TTM
Free cash flow (TTM)
$-5.21M
+67.6% vs year-ago TTM
EPS
$1.50
+412.5% vs prior year
Dividend per share
$0.25
Shares outstanding
40.45M
-1.0% vs prior year
Net cash
$37.22M
as of Jun 30, 2026
Operating margin
-754.4%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORMP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1176309
- Former names
- Integrated Security Technologies, Inc. (until Apr 10, 2006); IGUANA VENTURES LTD (until Jun 10, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2021 Aug 31, 2021 |
FY 2020 Aug 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.0M | — | $1.3M | $2.7M | $2.7M |
| Operating income | -$15.1M | -$12.8M | -$15.8M | -$24.2M | -$11.8M |
| Net income | $64.0M | -$19.1M | $5.1M | -$23.0M | -$11.5M |
| Diluted EPS | $1.50 | -$0.48 | $0.14 | — | — |
| Operating cash flow | -$9.1M | -$8.4M | -$10.3M | -$21.2M | -$12.4M |
| Free cash flow | -$9.2M | -$8.4M | -$10.5M | -$21.6M | -$12.5M |
| Total assets | $230.9M | $155.3M | $220.6M | $128.0M | $44.6M |
| Stockholders' equity | $199.7M | $146.3M | $163.8M | $115.8M | $32.9M |
| Cash and investments | $59.7M | $3.4M | $68.6M | $89.8M | $32.8M |
| Total debt | $825,000 | $372,000 | $51.6M | $403,000 | $75,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 17, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Aug 3, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Jun 30, 2026 | Jun 25, 2026 |
| 10-Q | Quarterly report | May 19, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets
|
Mar 31, 2026 | Mar 25, 2026 |
All 941 Oramed Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.